Compare GLSI & HCAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLSI | HCAC |
|---|---|---|
| Founded | 2006 | 2025 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.7M | 294.9M |
| IPO Year | 2020 | 2025 |
| Metric | GLSI | HCAC |
|---|---|---|
| Price | $15.90 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $57.00 | N/A |
| AVG Volume (30 Days) | ★ 116.2K | 103.6K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $9.92 |
| 52 Week High | $34.10 | $10.18 |
| Indicator | GLSI | HCAC |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 52.17 |
| Support Level | $14.44 | $10.05 |
| Resistance Level | $19.97 | $10.18 |
| Average True Range (ATR) | 1.36 | 0.01 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 35.28 | 40.00 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Hall Chadwick Acquisition Corp is a blank check company.